Action Defence Therapeutics - DTC

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

1,07

Prix Achat

1,01

Prix Vente

1,30

Volume échangé

5 600

1,05 Fourchette du Jour 1,07

0,48 Plage de 52 semaines 1,92

Clôture Veille

1,10

Ouverture

1,05

Dernière Transaction

300

1.07

Dernière heure de transaction

Volume moyen (3 m)

92 683

Volume financier

VWAP

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022...

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to...

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC:...

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER Vancouver, BC, Canada...

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire...

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN...

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.1	-8.54700854701	1.17	1.25	1.05	24746	1.15835851	CS
4	-0.1	-8.54700854701	1.17	1.4	0.96	72100	1.18293282	CS
12	0.44	69.8412698413	0.63	1.66	0.6	92683	1.16823924	CS
26	0.53	98.1481481481	0.54	1.66	0.49	55997	1.03250378	CS
52	-0.63	-37.0588235294	1.7	1.92	0.48	46836	1.02187843	CS
156	-3.23	-75.1162790698	4.3	4.85	0.48	26302	1.78309539	CS
260	-0.68	-38.8571428571	1.75	8.15	0.48	23129	2.19756988	CS

DTC - Frequently Asked Questions (FAQ)

What is the current Defence Therapeutics share price?

The current share price of Defence Therapeutics is $ 1,07

What is the 1 year trading range for Defence Therapeutics share price?

Defence Therapeutics has traded in the range of $ 0,48 to $ 1,92 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
CRVCCross River Ventures Corp	$ 0,01 (100,00%)	2k
LIVELive Energy Minerals Corp	$ 0,92 (84,00%)	1,21k
FFNT4Front Ventures Corp	$ 0,025 (66,67%)	6k
LIONGlobal Li Ion Graphite Corp	$ 0,04 (60,00%)	860,9k
TNJBoba Mint Holdings Ltd	$ 0,15 (50,00%)	338k
SGROSierra Grande Minerals Inc	$ 0,04 (-60,00%)	4,5k
WLLWWillow Biosciences	$ 0,015 (-57,14%)	252,1k
STKTStickIt Technologies Inc	$ 0,005 (-50,00%)	1 000
AVM.XAvarone Metals Inc	$ 0,005 (-50,00%)	10k
PLTOPluto Ventures Inc	$ 0,10 (-44,44%)	5k
TWOH.XTwo Hands Corporation	0,005 (0,00%)	22,21M
CACRKWG Resources Inc	$ 0,04 (-11,11%)	4,62M
QIMCQuebec Innovative Materials Corp	$ 0,235 (-6,00%)	2,61M
ELEMElement79 Gold Corp	$ 0,02 (-20,00%)	2M
NFLDExploits Discovery Corp	$ 0,035 (-22,22%)	1,96M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Defence Therapeutics Inc (DTC)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

DTC Dernières nouvelles

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS

DTC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Defence Therapeutics Inc (DTC) Cours

Defence Therapeutics Inc (DTC)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

DTC Dernières nouvelles

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS

DTC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités